Tivantinib, in combination with other tyrosine kinase inhibitors such as erlotinib and sorafenib, showed a promising therapeutic approach for EGFR-Mutant NSCLC and HCC, respectively [59,60]. Here, EGFR is linked to non-small cell lung carcinoma.